On Oct. 27, 2020, Moderna announced that the Medicines and Healthcare products Regulatory Agency (MHRA) in the UK had started the rolling review process of mRNA-1273, the Companyﾒs vaccine candidate against COVID-19.

This announcement followed positive results from a preclinical viral challenge study of mRNA-1273 and the positive interim analysis of the Phase 1 study of mRNA-1273 in adults (ages 18-55 years) and older adults (ages 56-70 and 71+) published in the New England Journal of Medicine.